Exploring the Potential Impact of RSV (Respiratory Syncytial Virus) Vaccines in Adult Population

A panel of medical experts discuss the prevalence of RSV in adults.

Adam C. Welch, PharmD, MBA, FAPhA, leads a panel discussion surrounding complications related to RSV infection.

Traditionally thought of as a pediatric disease, RSV also affects older patient populations.

The panel measures the significance of an RSV vaccine in relation to other vaccines in circulation.

Dr Welch leads a conversation regarding strategies to increase awareness of respiratory syncytial virus.

Financial impacts associated with respiratory syncytial virus infection are highlighted.

The panel discusses potential therapy options for adults infected with respiratory syncytial virus.

Key opinion leaders discuss ongoing clinical trials for respiratory syncytial virus vaccines.

Experts discuss strategies to prepare for the oncoming respiratory diseases season.

Vaccine hesitancy is a significant barrier to optimal RSV vaccine rollout.

Experts highlight the potential obstacles for RSV vaccines.

Experts discuss the financial needs for RSV vaccines through a payer lens.

The panel offers strategies for being proactive .

Discussion surrounding promotion of RSV vaccine awareness is further discussed.

In their closing thoughts, the panelists provide their key takeaways regarding immunizing against RSV.